Avid Stockholders Approve Transaction with GHO and Ampersand
30 janv. 2025 16h05 HE
|
Avid Bioservices, Inc
TUSTIN, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO) (“Avid” or the “Company”), a dedicated biologics contract development and manufacturing organization (“CDMO”)...
Avid Reminds Stockholders to Vote Today FOR the Transaction with GHO and Ampersand
22 janv. 2025 16h05 HE
|
Avid Bioservices, Inc
TUSTIN, Calif., Jan. 22, 2025 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO) (“Avid” or the “Company”), a dedicated biologics contract development and manufacturing organization (“CDMO”)...
Avid Recommends Stockholders Follow Recommendations of ISS and Glass Lewis and vote FOR the Transaction with GHO and Ampersand
21 janv. 2025 08h00 HE
|
Avid Bioservices, Inc
TUSTIN, Calif., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO) (“Avid” or the “Company”), a dedicated biologics contract development and manufacturing organization (“CDMO”)...
Avid Bioservices Files Investor Presentation Highlighting Value Maximizing Transaction with GHO and Ampersand
08 janv. 2025 17h15 HE
|
Avid Bioservices, Inc
TUSTIN, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO) (“Avid” or the “Company”), a dedicated biologics contract development and manufacturing organization (“CDMO”)...
Avid Bioservices Announces Expiration of Hart-Scott-Rodino Waiting Period for Pending Acquisition by GHO and Ampersand
30 déc. 2024 09h00 HE
|
Avid Bioservices, Inc
TUSTIN, Calif., Dec. 30, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO) (“Avid” or the “Company”), a dedicated biologics contract development and manufacturing organization (“CDMO”)...
Avid Bioservices Recommends Stockholders Vote FOR Value Maximizing Transaction
18 déc. 2024 16h35 HE
|
Avid Bioservices, Inc
TUSTIN, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO) (“Avid” or the “Company”), a dedicated biologics contract development and manufacturing organization (“CDMO”)...
Avid Bioservices Reports Financial Results for Second Quarter Ended October 31, 2024
10 déc. 2024 16h05 HE
|
Avid Bioservices, Inc
TUSTIN, Calif., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...
Avid Bioservices to be Acquired by GHO Capital Partners and Ampersand Capital Partners in $1.1 Billion Transaction
06 nov. 2024 18h04 HE
|
Avid Bioservices, Inc
TUSTIN, Calif. and LONDON and BOSTON, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO) (“Avid” or the “Company”), a dedicated biologics contract development and manufacturing...
Avid Bioservices to Participate in Craig-Hallum Bioprocessing Conference
12 sept. 2024 16h05 HE
|
Avid Bioservices, Inc
TUSTIN, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...
Avid Bioservices Reports Financial Results for First Quarter Ended July 31, 2024
09 sept. 2024 16h05 HE
|
Avid Bioservices, Inc
-- Recorded First Quarter Revenue of $40.2 Million -- -- Signed $66 Million in Net New Business, Resulting in Backlog of $219 Million -- -- Maintained FY2025 Revenue Guidance of Between $160...